Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female Chinese subjects aged 18-65 years (including 65) at screening.~* Subjects meeting the ICD-10 (Classification of Mental and Behavioral Disorders) criteria for schizophrenia (F20.X).~* Subjects who are in acute phase of schizophrenia and are appropriate to receive intramuscular medication for at least 3 days~Exclusion Criteria:~* History of clinically significant physical illness especially myocardial infarction, non compensatory heart failure etc.~* Subjects receiving an investigational agent in the previous 3 months prior to screening.~* Use of antipsychotic agents within 12 hours or parenteral benzodiazepines within 4 hours prior to randomization and during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Intramuscular ziprasidone (Type: EXPERIMENTAL): None
- Intramuscular haloperidol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).